$86.43
5.45% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US09627Y1091
Symbol
BPMC
Sector
Industry

Blueprint Medicines Corp. Stock price

$86.43
-6.31 6.80% 1M
-3.95 4.37% 6M
-5.81 6.30% YTD
+36.38 72.69% 1Y
-11.38 11.63% 3Y
+8.47 10.86% 5Y
+67.56 358.03% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-4.98 5.45%
ISIN
US09627Y1091
Symbol
BPMC
Sector
Industry

Key metrics

Market capitalization $5.47b
Enterprise Value $5.45b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 15.03
P/S ratio (TTM) P/S ratio 15.09
P/B ratio (TTM) P/B ratio 17.05
Revenue growth (TTM) Revenue growth 60.80%
Revenue (TTM) Revenue $362.80m
EBIT (operating result TTM) EBIT $-355.96m
Free Cash Flow (TTM) Free Cash Flow $-347.59m
Cash position $763.60m
EPS (TTM) EPS $-3.42
P/E forward negative
P/S forward 11.03
EV/Sales forward 10.99
Short interest 7.21%
Show more

Is Blueprint Medicines Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Blueprint Medicines Corp. Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Blueprint Medicines Corp. forecast:

14x Buy
74%
4x Hold
21%
1x Sell
5%

Analyst Opinions

19 Analysts have issued a Blueprint Medicines Corp. forecast:

Buy
74%
Hold
21%
Sell
5%

Financial data from Blueprint Medicines Corp.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
363 363
61% 61%
100%
- Direct Costs 31 31
30% 30%
8%
332 332
83% 83%
92%
- Selling and Administrative Expenses 305 305
32% 32%
84%
- Research and Development Expense 367 367
19% 19%
101%
-341 -341
32% 32%
-94%
- Depreciation and Amortization 15 15
39% 39%
4%
EBIT (Operating Income) EBIT -356 -356
32% 32%
-98%
Net Profit -205 -205
63% 63%
-57%

In millions USD.

Don't miss a Thing! We will send you all news about Blueprint Medicines Corp. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Blueprint Medicines Corp. Stock News

Neutral
InvestorPlace
about one month ago
With the market struggling amid rising recession fears, now may be the ideal time to consider biotech stocks. First, the sector itself is a financially lucrative one.
Neutral
Seeking Alpha
about one month ago
Blueprint Medicines Corporation (NASDAQ:BPMC ) Q2 2024 Earnings Conference Call August 1, 2024 8:00 AM ET Company Participants Jenna Cohen - Vice President-Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Christy Rossi - Chief Operating Officer Mike Landsittel - Chief Financial Officer Fouad Namouni - President-Research & Development Conference C...
Neutral
PRNewsWire
about one month ago
-- Achieved $114.1 million in AYVAKIT net product revenues in the second quarter 2024 -- -- Raising AYVAKIT net product revenue guidance to $435 million to $450 million for 2024 -- -- Initiated Phase 1 healthy volunteer trial of wild-type KIT inhibitor BLU-808 -- CAMBRIDGE, Mass. , Aug. 1, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, prov...
More Blueprint Medicines Corp. News

Company Profile

Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Head office United States
CEO Kathryn Haviland
Employees 655
Founded 2008
Website www.blueprintmedicines.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today